Brent Sabatini - 22 Feb 2026 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Signature
/s/ Vanina de Verneuil, Attorney-In-Fact
Issuer symbol
VIR
Transactions as of
22 Feb 2026
Net transactions value
-$13,631
Form type
4
Filing time
24 Feb 2026, 19:13:34 UTC
Previous filing
18 Feb 2026
Next filing
26 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sabatini Brent SVP, Chief Accounting Officer C/O VIR BIOTECHNOLOGY, INC., 1800 OWENS STREET, SUITE 900, SAN FRANCISCO /s/ Vanina de Verneuil, Attorney-In-Fact 24 Feb 2026 0002037272

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Award $0 +25,000 +52% $0.000000 72,872 22 Feb 2026 Direct F1
transaction VIR Common Stock Sale $13,631 -1,829 -2.5% $7.45 71,043 23 Feb 2026 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Award $0 +50,000 $0.000000 50,000 22 Feb 2026 Common Stock 50,000 $7.56 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
F2 Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person.v
F3 25% of the shares subject to the stock option will vest and become exercisable on February 22, 2027, and the remaining shares will vest in 36 equal monthly installments thereafter.